PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer

Bookmark and Share
Published: 4 May 2021
Views: 681
Rating:
Save
Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France

Dr Sophie Postel-Vinay speaks to ecancer about the PIPSeN trial. Initially, she explains the background of this trial.

PIPSeN is a randomised, double-blind phase II study that evaluated the PARPi olaparib as maintenance treatment in patients with platinum-sensitive advanced NSCLC.

Dr Postel-Vinay then discusses the methodology and key results of this trial. PIPSeN was terminated early with only 50% of the pre-planned patient population available for analysis, thus being statistically underpowered.

She concludes that although well-tolerated, olaparib maintenance did not improve median PFS nor median OS in this sample of patients with platinum-sensitive NSCLC.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.